Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The market size for weight loss drugs based on glucagon-like peptide (GLP) -1 agonists has seen a robust expansion in the past few years. This market is forecasted to escalate from a value of $13.38 billion in 2024 to $15.63 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.9%. The historical growth of this sector has been stimulated by several factors, such as the growing incidence of obesity, an increase in type 2 diabetes cases, heightened awareness about health risks associated with obesity, an upsurge in healthcare expenditure, a rising emphasis on managing chronic diseases, and enhanced accessibility to healthcare services.
What Growth Rate Is Forecasted for the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market by 2029?
The market size of glucagon-like peptide (GLP)-1 agonists weight loss drugs is projected to experience a significant surge in the coming years, reaching a value of $28.91 billion in 2029 with a 16.6% compound annual growth rate (CAGR). This expected growth in the forecasted period is due to a rising demand for efficient weight loss solutions, the extension of drug usage beyond diabetes care, an increase in investment in research and development, the adopted practice of personalized medicine, and intensified awareness through direct-to-consumer marketing. Forecasted trends include the creation of oral GLP-1 formulations, enhancements in sustained-release drug delivery, the incorporation of digital health tools for monitoring, the use of artificial intelligence in drug discovery and development, and innovations in peptide engineering for improved efficiency.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
Which Key Companies Are Shaping the Future of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.
Which Factors Are Driving Demand in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?
The growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market is likely to be bolstered by the increasing incidence of obesity. Defined as a health condition in which an excessive amount of body fat accumulates, posing a potential health threat, obesity rates are on the rise as a result of unhealthy dietary habits, characterized by an overconsumption of fast food and sugary beverages. This diet lacks proper nutrients and balance, leading to a significant number of people becoming obese, and thereby increasing the need for effective treatment alternatives. This has resulted in an uptick in the utilization of glucagon-like peptide (GLP)-1 agonist weight loss drugs, known for their ability to aid in weight loss and improve metabolic health. The World Health Organization, a Switzerland-based intergovernmental organization, reported in March 2024 that as of 2022, one in eight people worldwide were living with obesity. Of the 2.5 billion adults who were overweight, about 890 million were identified as obese. Furthermore, 43% of the entire adult populace was overweight, with 16% being categorized as obese. Hence, the glucagon-like peptide (GLP)-1 agonist weight loss drugs market is expected to expand due to the escalating prevalence of obesity.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
How Is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmented by Several Divisions?
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market covered in this report is segmented –
1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic, Wegovy, Rybelsus
2) By Liraglutide: Saxenda, Victoza
3) By Tirzepatide: Mounjaro, Zepbound
4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
What are the Emerging Market Trends Driving the Growth of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?
Major firms in the GLP-1 agonist weight loss drugs market are creating innovative treatment methods for obesity, aimed at boosting effectiveness and enhancing patient outcomes. These solutions essentially serve to imitate the GLP-1 hormone in the body, helping to control appetite, increase the feeling of fullness and aid in weight reduction. By improving the metabolic functions, these drugs contribute to sustainable weight management. In the context, Eli Lilly and Company, a pharmaceutical firm based in the US, was approved by the US Food and Drug Administration in November 2023 for Zepbound. This drug is designed for the long-term management of weight in adults struggling with obesity or overweight along with associated health conditions like type 2 diabetes or sleep apnea. By targeting GIP and GLP-1 hormone receptors, Zepbound helps reduce appetite and enhance metabolism.
Access The Full Report Here:
Which Regions Are Driving Growth in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
This Report Delivers Insight On:
1. How big is the glucagon-like peptide (glp)-1 agonists weight loss drugs market, and how is it changing globally?
2. Who are the major companies in the glucagon-like peptide (glp)-1 agonists weight loss drugs market, and how are they performing?
3. What are the key opportunities and risks in the glucagon-like peptide (glp)-1 agonists weight loss drugs market right now?
4. Which products or customer segments are growing the most in the glucagon-like peptide (glp)-1 agonists weight loss drugs market?
5. What factors are helping or slowing down the growth of the glucagon-like peptide (glp)-1 agonists weight loss drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model